Recognizes Rett Syndrome Awareness Month* Provides update on early-stage pipeline prioritization Newron Pharmaceuticals S.p.A. ("Newron"), a research and development company focused on novel central ...
MILAN--(BUSINESS WIRE)--Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the ...
Milan, Italy, July 1, 2022 – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of ...
Milan, Italy, December 29, 2023, 07:00 am CET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients ...
MILAN, ITALY - April 23, 2026 (NEWMEDIAWIRE) - Newron Pharmaceuticals S.p.A. ("Newron") (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients ...
Milan, Italy, and Morristown, NJ, USA – March 24, 2026, 07:00 am CET – Newron Pharmaceuticals S.p.A. ("Newron") (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel ...
Newron Pharmaceuticals S.p.A. (“Newron”), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central nervous system (CNS) and pain, today ...
MILAN & MORRISTOWN, N.J., March 19, 2026--(BUSINESS WIRE)--Newron Pharmaceuticals S.p.A. ("Newron") (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies ...
Ravi Anand, M.D., Chief Medical Officer of Newron, commented: “We are very disappointed that the top-line results in the STARS study did not meet the study endpoints. The results of this well designed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results